Skip to main content

Table 2 Distribution of cardiovascular drugs among the study patients

From: Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment

Drugs

Bezafibrate

(n = 58)

Placebo

(n = 50)

p value

Beta blockers (%)

29 (50)

26 (52)

0.8

Nitrates (%)

43 (74)

37 (74)

0.99

Calcium antagonists (%)

37 (64)

32 (64)

0.98

Diuretics (%)

6 (10)

10 (20)

0.2

Antiplatelets (%)

39 (67)

36 (72)

0.6

Angiotensin converting enzyme inhibitors (%)

8 (14)

3 (6)

0.2